TORONTO, May 15, 2025–(BUSINESS WIRE)–Kontrol Technologies Corp. (CBOE.CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company”) announces its results for the three months ended March 31, 2025. A complete set of the Financial Statements and Management’s Discussion & Analysis have been filed on SEDAR (www.sedarplus.ca). “As of Q1 2025 we have streamlined the Company and
Instil Bio Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS,
Jelmyto Sales: $20.3 million in Q1 2025, 8% year-over-year growth. Revenue Growth: Driven by 12% underlying demand growth. R&D Expenses: $19.9 million in Q1 2025, up from $15.5 million in Q1 2024. SG&A Expenses: $35 million in Q1 2025, up from $27.3 million in Q1 2024. Net Loss: $43.8 million or $0.92 per share in
Generation Bio Co. – Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA – Lead target and portfolio strategy to be announced mid-2025 – Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May
Total Revenue: $112.6 million, up 1.6% year over year. Non-GAAP Gross Margin: 35.8%. Adjusted EBITDA: $14.9 million, up 17% year over year. Non-GAAP EPS: $0.88, up 13% year over year. North America Revenue: $49.4 million, up 11% year over year. International Revenue: $63.2 million, down 5% year over year. GAAP Operating Expenses: $30 million, down
Revenue: $139 million in Q1 2025, representing 28% growth over Q1 2024. Crysvita Revenue: $103 million, with 25% growth over 2024; $41 million from North America, $55 million from Latin America and Turkey, $7 million from Europe. Dojolvi Revenue: $17 million, consistent with steady growth. Evkeeza Revenue: $11 million, with increasing demand following launches outside
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filing Successful FDA Type
Net Sales: $137.3 million in Q1 2025, up 33% from Q4 2024. Patient Growth: Over 17,000 patients on Rezdiffra by end of Q1 2025, up from 11,800 in Q4 2024. Prescriber Penetration: 70% of 6,000 top target prescribers have prescribed Rezdiffra. R&D Expenses: $44.2 million in Q1 2025, down from $71.2 million in Q1 2024.
Research and Development Expenses: $13.4 million for Q1 2025, down from $19.8 million in Q1 2024. General Administrative Expenses: $7 million for Q1 2025, down from $10.1 million in Q1 2024. Net Loss: $17.7 million for Q1 2025, compared to $26.9 million in Q1 2024. Cash, Cash Equivalents, and Marketable Securities: $226.6 million as of
Total Revenue: $66.8 million for Q1, a 12% increase from Q1 2024. Subscription Software Revenue: $32.2 million in Q1, up 30% year-over-year. Gross Margin: 52.8% in Q1, an increase of 4.3 percentage points from Q4. Adjusted EBITDA: Negative $12.2 million, improved from negative $45.6 million in Q1 2024. Cash and Marketable Securities: $222 million at